On April 7, at AACR, our therapeutic antibody collaborator Syncromune delivered an oral presentation unveiling clinical data of its SYNC-T technology for the first time! Initial clinical data of SYNC-T SV-102, which includes our clinical stage CTLA-4 monoclonal antibody YH001 and CD40 agonistic monoclonal antibody YH003, demonstrate a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer.

Reference:

• 1.AACR News Release: A Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients with Metastatic Prostate Cancer
• 2.GlobeNewswire-Syncromune^® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024
• AACR2024 abstract-CT026 - Systemic responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)